Clinical Trials Interview June 2022, page-7

This is from PAA's last valuation.
"According to Spruson and Ferguson, PharmAust’s patent attorneys, the patents expire on or about the end of April 2019 depending on jurisdiction. A five year extension of term, to April 2024, has been allowed in Switzerland, Germany, France the UK and Italy."
But I have read somewhere that they start to run out next year.

https://pharmaust.com/wp-content/uploads/2017/11/150908_Actuity_-PHARMAUST-valuation-08-09-15signed.pdf
NB that is worth a read, the ML part anyway, especially the part on human patents.

"Not sure what others think but I'm for selling the canine license at a reduced price if it fills the coffers and expedites the other applications. But we are all in different situations."

If we need further Capital well we would probably have no choice unless there is a new valuation done then PAA maybe able to borrow against IP.
The trial in Texas changes the game IMO .This is from a Densy post.
More info here: https://hotcopper.com.au/posts/61354514/single
As always follow the money.

Good luck to all